Clinical trials: Oncologic Patients
Glioblastoma
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
PROPHETIC GBM - Predicting response patterns to treatment in Glioblastoma (GBM) oncology patients based on host response evaluation during anti-cancer treatments
- Trial name
- PROPHETIC (NCT04219475)
- Where
- 4 sites in Israel
- Volunteers
- 1,000 people
- Sponsor
- OncoHost Ltd.
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after…
- Trial name
- STELLAR (NCT02796261)
- Testing
- Eflornithine, Lomustine
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- Orbus Therapeutics, Inc.
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Oncology
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated…
- Trial name
- NCT04299880
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma America, Inc.
Nursing Students
Cancer Symptom Management in Nursing Students
Ensuring that nursing students learn the symptoms seen in cancer.
- Trial name
- NCT06695702
- Testing
- the effect of work-based learning on the level of knowledge
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bilecik Seyh Edebali Universitesi
Myelodysplastic Syndrome (MDS)
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
Primary Outcome Measures: To evaluate the efficacy of treatment with Azacitidine in patients with transfusion-dependent, low risk International Prognostic Scoring System (IPSS) 0 int-1, Myelodysplastic Syndrome (MDS) without…
- Trial name
- ABRAZA (NCT01338337)
- Testing
- Azacitidine
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
A Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of Pennsylvania
A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION
To gain understanding about the impact of visual art making on biomarkers, such as cortisol, alpha amylase, oxytocin, etc. to examine whether and to what extent there are changes in levels of stress and immune function in…
- Trial name
- NCT03155672
- Testing
- Art therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients
The primary purpose of this study is to measure the association between baseline expression of the senescence effector protein p16INK4a and myelosuppression due to chemotherapy in patients with breast cancer.
- Trial name
- NCT01305954
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer
Open Dialogue About Complementary Alternative Medicine
The purpose of this phase III parallel-group randomized controlled trial is to assess the efficacy of open dialogue about complementary alternative medicine integrated in conventional oncology care (ODC-COC).
- Trial name
- NCT04299451
- Testing
- Open dialogue about CAM
- Where
- Denmark
- Volunteers
- 210 people
- Sponsor
- Vejle Hospital
Pain Management
Measuring the Effects of Therapeutic Education Program "Caratif" Patient Under Strong Opioids Versus Standard Taking Charge of Patient Pain Receiving Opioid Therapy in Medical Oncology.
A first empirical evidence on the difficulties of observance of morphine in cancer patients invited a multidisciplinary team to initiate an innovative quality approach.
- Trial name
- NCT02862002
- Testing
- therapeutic education of type "caratif, Standard care
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Breast Neoplasms, Breast Cancer
IRELAND Trial: A Translational Biomarker and Exercise Study During Neoadjuvant Breast Cancer Therapy
The goal of this clinical trial is to learn whether a physiotherapy-led exercise programme delivered during treatment before surgery (neoadjuvant therapy) for breast cancer can improve physical fitness, quality of life, and how…
- Trial name
- IRELAND (NCT07799337)
- Testing
- Physiotherapist-Led Personalised Adaptive Exercise Programme
- Volunteers
- 250 people
- Sponsor
- National University of Ireland, Galway, Ireland
Adherence, Patient
Observational Study to Assess Adherence Oral Anticancer Therapies
Oral anticancer treatments are increasingly numerous. They represent an additional alternative in the therapeutic arsenal of the clinician, and appear to satisfy patients who prefer this route of administration over intravenous…
- Trial name
- ObservAG (NCT03195972)
- Testing
- Drug diary filling
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Solid Tumours
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice…
- Trial name
- NCT02093351
- Testing
- Olaparib, Tamoxifen, Anastrozole
- Where
- 14 sites in Belgium, Denmark and 3 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Blood Cancer, Multiple Myeloma (MM)
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress.
- Conditions
- Blood Cancer, Multiple Myeloma (MM), Lymphoma
- Trial name
- NCT06817759
- Testing
- Virtual Reality Hypnosis, VRH : Beach, VRH : Forest
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Dermatology and Oncology
Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study.
Patients with a BRAF mutated melanoma are usually treated in France by a first line of immunotherapy followed by a second line that combines a BRAF inhibitor (dabrafenib, vemurafenib, encorafenib) and a MEK inhibitor (trametinib…
- Trial name
- CHLORO-DATRAM (NCT04760080)
- Testing
- pre-treatment data, during study treatment
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Hospices Civils de Lyon
Oncological Disease, Fertility Preservation
Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone
Fertility preservation is a crucial aspect of care for oncological patients undergoing gonadotoxic treatments such as chemotherapy, radiotherapy, or surgery, which can significantly reduce ovarian reserve and cause infertility or…
- Trial name
- NCT07546123
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.